Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 314

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Neuromodulation in epilepsy: state-of-the-art approved therapies

Ryvlin, Philippe, Rheims, Sylvain, Hirsch, Lawrence J, Sokolov, Arseny, Jehi, Lara·2021·The Lancet Neurology

Abstract

Three neuromodulation therapies have been appropriately tested and approved in refractory focal epilepsies: vagus nerve stimulation (VNS), deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS), and closed-loop responsive neurostimulation of the epileptogenic zone or zones. These therapies are primarily palliative. Only a few individuals have achieved complete freedom from seizures for more than 12 months with these therapies, whereas more than half have benefited from long-term reduction in seizure frequency of more than 50%. Implantation-related adverse events primarily include infection and pain at the implant site. Intracranial haemorrhage is a frequent adverse event for ANT-DBS and responsive neurostimulation. Other stimulation-specific side-effects are observed with VNS and ANT-DBS. Biomarkers to predict response to neuromodulation therapies are not available, and high-level evidence to aid decision making about when and for whom these therapies should be preferred over other antiepileptic treatments is scant. Future studies are thus needed to address these shortfalls in knowledge, approve other forms of neuromodulation, and develop personalised closed-loop therapies with embedded machine learning. Until then, neuromodulation could be considered for individuals with intractable seizures, ideally after the possibility of curative surgical treatment has been carefully assessed and ruled out or judged less appropriate.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(21)00300-8

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Cited by

See all 314

Metadata

Authors
Ryvlin, P., Rheims, S., Hirsch, L. J., Sokolov, A., & Jehi, L.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2021-12
Volume
20
Issue
12
Pages
1038-1047
ISSN
1474-4422 (ISSN-L)
OpenAlex
W3208234271
Cited by
314
References
82
FWCI
26.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuromodulation in epilepsy: state-of-the-art approved therapies. https://app.cochat.ai/papers/10.1016/s1474-4422(21)00300-8
The paper
Ryvlin, P., Rheims, S., Hirsch, L. J., Sokolov, A., & Jehi, L. (2021). Neuromodulation in epilepsy: state-of-the-art approved therapies. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(21)00300-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.